Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Astellas Pharma: Clinical Trials & FDA Approval Profile

Astellas Pharma (Tokyo, JP / Northbrook, IL) sponsors 63 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 28 active protocols (15 recruiting now), 28 completed protocols, and 27 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)11.1%
Median Closed Enrollment vs National (145 pts)149 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Astellas Pharma
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)63
Active Pipeline (Recruiting Now)28 (15)
Completed vs Stopped Early28 / 7 (11.1%)
Median Closed Actual Enrollment149 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals27 (8 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Astellas Pharma
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA9
Northwestern Memorial and Lurie Cancer CenterChicago, IL8
Memorial Sloan Kettering Cancer CenterNew York, NY7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Astellas Pharma
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06901531A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase IIIRECRUITING
NCT07566052A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPhase IIIRECRUITING
NCT07005154A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerPhase IIRECRUITING
NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderPhase IIRECRUITING
NCT07409272A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People WithPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Astellas Pharma Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI